News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Ireland’s largest ever cancer research programme enters next phase • healthcare-in-europe.com
Ireland's Minister for Further and Higher Education, Research, Innovation and Science, James Lawless TD, launched Phase 2 of Ireland’s leading and largest ever cancer research programme, Precision Oncology Ireland (POI).
GLP-1 agonists may interfere with cancer imaging, new study finds • healthcare-in-europe.com
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET/CT scans, new research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.¹
Advancing genomic medicine from promise to practice with digital technology • healthcare-in-europe.com
Stroke patients in four NHS hospitals are now receiving genetic tests that determine whether a commonly prescribed drug will work for them – a breakthrough that could transform treatment for millions. Digital approaches are spearheading a drive to help make genomic medicine part of everyday care. The role of digital tools was a central theme at the HETT (Healthcare Excellence Through Technology) North conference in Manchester.
Immune system researchers receive Nobel Prize 2025 in Medicine • healthcare-in-europe.com
The body’s powerful immune system must be regulated, or it may attack our own organs. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body.
How leukemia cells trick the immune system • healthcare-in-europe.com
A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body’s immune system. By developing an antibody that blocks the mechanism, the researchers could restore the immune system’s ability to kill the cancer cells in laboratory trials and in mice.
Endometrial cancer: visceral fat may drive aggressiveness • healthcare-in-europe.com
High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, new research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) shows.¹
What is ‘herd immunity’ and how can it help eliminate infectious diseases? • healthcare-in-europe.com
When forest fire experts want to proactively decrease the risk of wildfires, they create small, controlled burns to limit the amount of fuel available to the fire. This reduces the fire’s ability to spread. The concept of controlling infectious disease is similar.
Hormone replacement therapy after breast cancer: a risk worth taking? • healthcare-in-europe.com
Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including researchers from University College London (UCL).
Rethinking Healthcare: AI as a Catalyst for Change • healthcare-in-europe.com
Healthcare stands at a crossroads. With an impending shortage of 11 million healthcare workers by 2030 and millions dying annually from poor-quality care, the industry desperately needs transformation. Dr. Alex Ng from Tencent Healthcare explores how artificial intelligence is emerging as a powerful catalyst—not to replace human expertise, but to amplify it.
What the clinic does not say • healthcare-in-europe.com
This year, the Journées Francophones de Radiologie (JFR) will carry a clinical ambition as simple as it is essential: to shine a spotlight on those who are often overlooked. Under the presidency of Professor Mathieu Lederlin, thoracic radiologist at Rennes University Hospital, vulnerable patients will be at the heart of the annual meeting of the French Society of Radiology that will unfold October 3-6 at its iconic venue at the Palais des Congrès in Paris.
“Very rarely a chance of heart attack or death” – Wait, what? • healthcare-in-europe.com
Hospitalists frequently discuss the risks associated with tests, treatments, and/or surgical procedures with their patients. But is everyone in the clear on what a “slight risk of complications” actually means? A session on the meaning of risk to patients and how to effectively communicate risk was discussed at SHM Converge 2025, the annual meeting of the Society of Hospitalist Medicine held in Las Vegas in April.
Managing inpatients with substance abuse disorders • healthcare-in-europe.com
The number of patients with substance abuse disorders who are admitted to hospitals as inpatients has been steadily increasing. Hospitalists attending SHM Converge 2025, the annual meeting of the Society of Hospital Medicine (SHM) in Las Vegas this spring, were given practical advice on how to treat these patients.
What's holding back the digital transformation of NHS healthcare • healthcare-in-europe.com
Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools and staff training, finds a major new UK study led by researchers from University College London (UCL).
3D bioprinting to solve donor organ shortage • healthcare-in-europe.com
Organ donors can save lives, for example those of patients with kidney failure. Unfortunately, there are too few donors, and the waiting lists are long. 3D bioprinting of (parts of) organs may offer a solution to this shortage in the future. But printing living tissues, bioprinting, is extremely complex and challenging.
NSCLC: Surgical combination therapy may prolong disease control • healthcare-in-europe.com
A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).